Revised March 2012
What We Do:
NIDA supports state-of-the-art genetic/genomic and epigenetic research in the basic, clinical and population sciences of drug addiction. Elucidation of genetic factors, their interactions with behavioral, social, and physical environments, and their relationship to specific phenotypes and associated outcomes including HIV/AIDS, are critical to determining addiction vulnerabilities, and will ultimately help facilitate diagnosis, treatment, and prevention.
NIDA funds a broad range of research in human and molecular genetics, model genetic organisms, pharmacogenetics, genetic epidemiology, genes and development, epigenetics, statistical genetics, and the ethical, legal and social implications of research on the genetic vulnerability of addiction.
- Support the discovery of gene variants and epigenetic modification associated with substance abuse and dependence.
- Promote and facilitate the integration of novel genetic/genomic hypotheses, laboratory and statistical methodologies into studies of substance abuse.
- Ensure training opportunities in addiction genetics for students and post-doctoral fellows.
- Support the translation of significant reproducible findings in genetics/genomics research into clinical applications.
Outlines NIDA’s drug abuse and addiction research strategic priorities for the next 5 years, focusing on prevention, treatment, HIV/AIDS, and other cross-cutting issues.